Literature DB >> 2137098

Identification of an interleukin-1 beta binding protein in human plasma.

J A Eastgate1, J A Symons, G W Duff.   

Abstract

A covalent cross-linking technique was used to bind iodinated interleukin-1 (IL1) alpha and beta to plasma proteins. One specific IL1 beta binding protein was observed, that when cross-linked to 125I-IL1 beta migrated to approximately 60 kDa on SDS-PAGE. The protein did not bind IL1 alpha. The 43 -kDa protein was partially purified using a wheat germ agglutinin affinity column. The isolated factor again specifically bound IL1 beta, and appeared to consist of single chain glycoprotein. The protein was heat stable and had a rapid association time with IL1 beta. This protein may be an important carrier molecule for IL1 beta in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137098     DOI: 10.1016/0014-5793(90)80106-s

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

Review 1.  Cytokines, receptors, and inhibitors.

Authors:  G Gehr; T Braun; W Lesslauer
Journal:  Clin Investig       Date:  1992-01

2.  Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist.

Authors:  J A Symons; P R Young; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

Review 3.  Regulation of serum amyloid A protein expression during the acute-phase response.

Authors:  L E Jensen; A S Whitehead
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

4.  The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.

Authors:  D Burger; R Chicheportiche; J G Giri; J M Dayer
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

5.  Purification and characterization of a novel soluble receptor for interleukin 1.

Authors:  J A Symons; J A Eastgate; G W Duff
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

6.  Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment.

Authors:  Anne M Lewis; Sheelu Varghese; Hui Xu; H Richard Alexander
Journal:  J Transl Med       Date:  2006-11-10       Impact factor: 5.531

7.  Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function.

Authors:  F Re; M Sironi; M Muzio; C Matteucci; M Introna; S Orlando; G Penton-Rol; S K Dower; J E Sims; F Colotta; A Mantovani
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

8.  A TLR4-interacting peptide inhibits lipopolysaccharide-stimulated inflammatory responses, migration and invasion of colon cancer SW480 cells.

Authors:  Madhusoodhanan Rakhesh; Moriasi Cate; Ramani Vijay; Anant Shrikant; Awasthi Shanjana
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

9.  Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor.

Authors:  G Bergers; A Reikerstorfer; S Braselmann; P Graninger; M Busslinger
Journal:  EMBO J       Date:  1994-03-01       Impact factor: 11.598

10.  Chemoattractants induce rapid release of the interleukin 1 type II decoy receptor in human polymorphonuclear cells.

Authors:  F Colotta; S Orlando; E J Fadlon; S Sozzani; C Matteucci; A Mantovani
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.